SCHEMBL614041

SCHEMBL614041

COc1ccc2[nH]c3c(C)c4ccnc(Cl)c4cc3c2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 2/20 0.58
DYRK1A Q13627 2/20 0.57
KDM4E B2RXH2 5/20 0.55
MAPT P10636 4/20 0.55
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
POLB P06746 2/20 0.55
RECQL P46063 2/20 0.55
TLR3 O15455 1/20 0.55
NR3C1 P04150 1/20 0.55
PKM P14618 1/20 0.55
RAB9A P51151 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
BCHE P06276 3/20 0.53
ALDH1A1 P00352 5/20 0.49
HSD17B10 Q99714 3/20 0.49
ACHE P22303 3/20 0.49
HPGD P15428 3/20 0.49
HTR2C P28335 2/20 0.49
DYRK3 O43781 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL612838 0.86 KIT (0.59) KITDYRK1AKDM4EMAPTMEN1
SCHEMBL9678106 0.84 KIT (0.55) KITDYRK1AKDM4EMAPTMEN1
SCHEMBL11096433 0.84 MAOA (0.55) KITDYRK1AKDM4EMAPTMEN1
SCHEMBL614042 0.83 MAOA (0.55) KITDYRK1AKDM4EMAPTNPSR1
SCHEMBL24277810 0.83 KIT (0.61) KITDYRK1AKDM4EMAPTMEN1
SCHEMBL13356168 0.83 KIT (0.67) KITDYRK1AKDM4EMAPTMEN1
SCHEMBL9678200 0.83 DYRK1A (0.59) KITDYRK1AKDM4EMAPTMEN1
SCHEMBL614704 0.82 KIT (0.53) KITDYRK1AKDM4EBCHEACHE
SCHEMBL2314351 0.82 KIT (0.55) KITDYRK1AKDM4EMAPTMEN1
SCHEMBL613967 0.81 KDM4E (0.63) KITDYRK1AKDM4EMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8604048-B2 Pyridocarbazole type compounds and applications thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-10 US disclosed
US-20120041017-A1 PYRIDOCARBAZOLE TYPE COMPOUNDS AND APPLICATIONS THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2012-02-16 US disclosed
US-20120041017-A1 PYRIDOCARBAZOLE TYPE COMPOUNDS AND APPLICATIONS THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2012-02-16 US disclosed
US-20120041017-A1 PYRIDOCARBAZOLE TYPE COMPOUNDS AND APPLICATIONS THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2012-02-16 US disclosed
US-7989467-B2 Use of indole-derived compounds for the preparation of a medicament that can be used to treat diseases related to the splicing process CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2011-08-02 US disclosed
WO-2010095042-A2 PYRIDOCARBAZOLE TYPE COMPOUNDS AND APPLICATIONS THEREOF CENTRE NATONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2010-08-26 WO disclosed
EP-1663219-B1 USE OF INDOLE-DERIVED COMPOUNDS FOR THE PREPARATION OF A MEDICAMENT THAT CAN BE USED TO TREAT DISEASES RELATED TO THE SPLICING PROCESS CENTRE NAT RECH SCIENT (FR) 2010-05-12 EP disclosed
US-20070054905-A1 Use of indole-derived compounds for the preparation of a medicament that can be used to treat diseases related to the splicing process CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041017-A1 PYRIDOCARBAZOLE TYPE COMPOUNDS AND APPLICATIONS THEREOF NLN, OPA1, PYCR1 KIT 4688/4885DYRK1A 3345/4885KDM4E 3884/4885
US-20070054905-A1 Use of indole-derived compounds for the preparation of a medicament that can be used to treat diseases related to the splicing process RBM17, BRCA1, SMN1; SMN2 KIT 2116/4885DYRK1A 3959/4885KDM4E 2967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.